Orchard Therapeutics Plc (ORTX) Return on Equity ROE from the third quarter 2023 to third quarter 2022 and annually, average high and low, overall ranking from Sep 30 2023 to Sep 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Orchard Therapeutics Plc  (NASDAQ: ORTX)

Orchard Therapeutics Plc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Orchard Therapeutics Plc in the third quarter 2023?
Orchard Therapeutics Plc recorded a cumulative net loss of $-73 million during 12 months ending in the third quarter 2023, resulting in a negative return on equity (ROE) of -74.94%.

Within the Biotechnology & Pharmaceuticals industry 87 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2023 from 2679 to 3650.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Equity Change -35.12 % -25.45 % -42.13 % -53.2 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -73 -85 -124 -151 -179
Return On Equity (TTM) -74.94 % -78.74 % -105.37 % -110.8 % -109.29 %
ORTX's Total Ranking # 3650 # 2679 # 3188 # 3877 # 0
Equity (TTM) in Millions 80 109 102 98 124
Seq. Equity Change -26.4 % 7.27 % 3.45 % -20.56 % -15.43 %
Seq. Net Income Change - - - - -

Back to ORTX Management Effectiveness >> ORTX's 5 Years Annual ROE >> Compare ORTX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 88
Sector # 567
Overall # 3650

Return On Equity Statistics
High Average Low
-50.38 %
-75.03 %
-110.8 %
(Dec 31 2019)   (Dec 31 2022)



  News about Orchard Therapeutics Plc Return on Equity ROE

Orchard Therapeutics: Pioneering Breakthrough Treatment while Navigating Financial Waters

Orchard Therapeutics: Breakthrough Treatment for Metachromatic Leukodystrophy and Financial Challenges
In a groundbreaking development, Orchard Therapeutics has received FDA approval for its therapy, Lenmeldy (atidarsagene autotemcel), making it the sole treatment available for eligible children with Early-onset Metachromatic Leukodystrophy (MLD) in the United States. This one-time treatment has demonstrated the potential to restore enzymatic function and effectively halt or slow down the progression of the disease. With a median follow-up of 6.76 years and some patients followed for up to 12 years, Lenmeldy has shown promising long-term results.
Metachromatic Leukodystrophy is a rare genetic disorder that affects the nervous system, leading to the loss of muscle control, cognitive decline, and ultimately a significantly shortened lifespan. Before the approval of Lenmeldy, there were no targeted treatments available for this devastating disease. The approval of this therapy offers hope to affected families and gives Orchard Therapeutics a significant edge in the biotechnology and pharmaceutical industry.



ORTX Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018
Total Equity in Millions 98 210 178 299 311
Y / Y Equity Change -53.2 % 17.66 % -40.36 % -3.9 % -
Net Income in Millions -151 -145 -152 -163 -230
Y / Y Net Income Change - - - - -
Return On Equity -153.32 % -68.87 % -85.17 % -54.62 % -74.03 %

Back to ORTX Management Effectiveness >> ORTX's 5 Years Annual ROE >> Compare ORTX ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ORTX's' Return on Equity at Yahoo Finance
ORTX's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ORTX's Competitors
Subscribers only: Roe for Orchard Therapeutics Plc's Suppliers
Subscribers only: Return On Equity for ORTX's Customers




Companies with similar Return On Equity at Sep 30 2023, within Healthcare Sector ROE

Date modified: 2026-09-26T07:35:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.